Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MA+AZA vs DA+AZA in Newly Diagnosed AML
NCT06345365Phase 3Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 3 trial of mitoxantrone-liposome in acute myeloid leukemia (AML), sponsored by Zhongnan Hospital of Wuhan University. Started Jan 2024; status: recruiting.
02
Drugs
mitoxantrone-liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06345365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345365.